Information Provided By: 
Fly News Breaks for January 10, 2018
UTHR, STDY
Jan 10, 2018 | 07:09 EDT
JMP Securities analyst Donald Ellis thinks the recent pullback in shares of SteadyMed (STDY) may have been due to comments from United Therapeutics (UTHR) about its own product pipeline. However, he views the dip as unwarranted, noting that United's RemoPro product would not be approved until 2020, if approved, and that its products do not address the issue of pain associated with treprostinil. The analyst, who expects SteadyMed's Tevyent to quickly take share from Remodulin, keeps an Outperform rating on SteadyMed shares.
News For STDY;UTHR From the Last 2 Days
There are no results for your query STDY;UTHR
